ICU Medical (NASDAQ:ICUI) Issues FY 2025 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 7.350-7.650 for the period, compared to the consensus EPS estimate of 6.370. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 5th. Raymond James Financial reduced their target price on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. KeyCorp dropped their price target on ICU Medical from $191.00 to $173.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 21st. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Finally, Piper Sandler boosted their price target on ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $176.50.

ICU Medical Price Performance

Shares of ICU Medical stock traded up $2.29 during trading on Thursday, reaching $129.67. The company’s stock had a trading volume of 429,593 shares, compared to its average volume of 267,995. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. ICU Medical has a 12-month low of $107.00 and a 12-month high of $196.26. The business has a 50 day moving average price of $123.82 and a 200-day moving average price of $128.19. The company has a market capitalization of $3.20 billion, a P/E ratio of -85.31 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, topping analysts’ consensus estimates of $1.44 by $0.66. The company had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.ICU Medical’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.56 earnings per share. As a group, sell-side analysts anticipate that ICU Medical will post 4.11 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Vivek Jain purchased 21,929 shares of the business’s stock in a transaction dated Thursday, August 14th. The stock was bought at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the acquisition, the chief executive officer directly owned 130,149 shares in the company, valued at $14,686,013.16. The trade was a 20.26% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Greenberg purchased 1,200 shares of the business’s stock in a transaction dated Wednesday, August 27th. The stock was bought at an average cost of $126.42 per share, with a total value of $151,704.00. Following the completion of the acquisition, the director owned 7,960 shares of the company’s stock, valued at approximately $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Lazard Asset Management LLC raised its stake in ICU Medical by 16,112.5% during the second quarter. Lazard Asset Management LLC now owns 10,376 shares of the medical instruments supplier’s stock valued at $1,371,000 after buying an additional 10,312 shares in the last quarter. AQR Capital Management LLC increased its position in ICU Medical by 2.5% in the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after acquiring an additional 229 shares during the period. Occudo Quantitative Strategies LP boosted its stake in ICU Medical by 4.6% during the 2nd quarter. Occudo Quantitative Strategies LP now owns 5,878 shares of the medical instruments supplier’s stock valued at $777,000 after purchasing an additional 261 shares in the last quarter. Captrust Financial Advisors boosted its stake in shares of ICU Medical by 113.3% during the 2nd quarter. Captrust Financial Advisors now owns 4,844 shares of the medical instruments supplier’s stock worth $640,000 after acquiring an additional 2,573 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of ICU Medical by 71.9% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,570 shares of the medical instruments supplier’s stock worth $604,000 after acquiring an additional 1,911 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.